| Document |
Document Title |
|
WO/2017/025560A1 |
The present invention relates to a process for the preparation of the compound N-(3,5-dimethylphenyl)-N'-(2-trifluoromethylphenyl) guanidine of formula (I) which comprises reacting a salt of a compound of formula (II) or a mixture of the...
|
|
WO/2017/027582A1 |
Compounds, pharmaceutical compositions, methods and kits are described for treating or preventing neurodegenerative diseases such as Alzheimer's disease.
|
|
WO/2017/023833A1 |
The present invention is directed to combination pharmacological treatments that induce a prolonged, modest decrease in core body temperature, to the range of ~95°F to ~98.5°F (~35°C to ~36.7°C) to mitigate and delay the early onset ...
|
|
WO/2017/018361A1 |
The present invention is a compound represented by general formula (A), a base and/or radical generator obtained by containing said compound, and the like. (In the formula: four R1 groups each independently represents a hydrogen atom or ...
|
|
WO/2017/011917A1 |
Methods for treating polycystic kidney disease (PKD) in a subject comprising administering a 5'-adenosine monophosphate (AMP)-activated protein kinase (AMPK) modulator or activator. Also kits comprising AMPK modulator or activators and i...
|
|
WO/2017/013573A1 |
In accordance with the present invention, disclosed herein is a fertilizer core particle and fertilizer granule. The fertilizer core particle has one or more fertilizer additives, one or more binders comprising a wax, and one or more pH ...
|
|
WO/2016/202125A1 |
Disclosed are an intermediate, N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-forma
midine]phenyl-2-propenamide (II), applicable in preparing AZD9291 (I) and a preparation method for the intermediate. Preparation steps comprise: ...
|
|
WO/2016/203069A1 |
The present invention relates to the production of ε-caprolactam by treating cyclohexanone oxime with salts derived from guanidinium cation, and in particular with the tosylate of cyanoguanidine ([CNG][TsO]). The invention of the presen...
|
|
WO/2016/201128A1 |
The present application provides, inter alia, chemical compounds useful as synthesis intermediates, said compounds comprising one or more guanidinium moieties and a hypervalent iodine atom. Methods for making these compounds are also pro...
|
|
WO/2016/199756A1 |
The ketone-based gas adsorbent according to the present invention is characterized by containing a primary amine compound. The primary amine compound is preferably at least one selected from the group consisting of hydrazide compounds, a...
|
|
WO/2016/193284A1 |
The present invention relates to compounds of formula (I) as defined herein, to processes for preparing them, to pesticidal, in particular insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising them and to method...
|
|
WO/2016/195077A1 |
This novel guanidine compound having excellent bactericidal activity is represented by formula [I]. (In the formula, Y represents a divalent group represented by formula [II] (wherein each of R7-R9 independently represents a hydrogen ato...
|
|
WO/2016/190227A1 |
Provided is a novel substance that is a physiologically active substance affecting gravity tropism. The gravity tropism regulator according to the present invention comprises, as an active ingredient, at least one kind of compound select...
|
|
WO/2016/180840A1 |
The present invention relates to the use of a catalyst of the formula (I) for the crosslinking of a curable composition. The catalyst of the formula (I) contains at least one aliphatic guanidine group. It is substantially odourless and n...
|
|
WO/2016/178130A1 |
The present invention relates to extended release liquid compositions of metformin. The extended release liquid compositions are in the form of suspensions or reconstituted powder for suspensions. Said extended release liquid composition...
|
|
WO/2016/176771A1 |
The present description relates to an anti-aging composition comprising at least one plant extract. The composition can comprise at least two different anti-aging agents, wherein one the anti-aging agent is a plant extract. The combinati...
|
|
WO/2016/176691A1 |
Methods for determining renal function in an animal subject, the method including measuring the concentration of β-aminoisobutyric acid (β-amino isobutyrate) (BAIB) in patients samples and determining the presence, likelihood, or progr...
|
|
WO/2016/176636A1 |
This invention relates to compounds that inhibit creatine transport and/or creatine kinase, pharmaceutical compositions including such compounds, and methods of utilizing such compounds and compositions for the treatment of cancer.
|
|
WO/2016/175357A1 |
The present invention relates to guanidine compounds for inhibiting mitochondrial oxidative phosphorylation (OXPHOS) and use thereof. More specifically, the present invention relates to a pharmaceutical composition for preventing or trea...
|
|
WO/2016/161921A1 |
Conjugate compounds having at least one of a moiety derived from ursodeoxycholic acid, or eicosapentaenoic acid, or docosahexaenoic acid, or rhein, or R- (+) -α-lipoic acid, or ursolic acid, or corosolic acid, or hydroxycitric acid, or ...
|
|
WO/2016/149233A1 |
Guanidine-functionalized perlite particles are provided. Nonwoven articles are also provided, including a fibrous porous matrix and guanidine-functionalized perlite particles enmeshed in the fibrous porous matrix. Laminated articles are ...
|
|
WO/2016/141460A1 |
Provided herein are therapies, and methods using that therapy, in the treatment of one or more of Type 2 diabetes (T2D), obesity, glucose intolerance and insulin resistance or to control weight gain in subjects. In particular, the subjec...
|
|
WO/2016/134251A1 |
Homogeneous immunoassays that allow for compensation of background signals inherent in samples and reagents. The use of homogeneous immunoassays for the detection of the presence or amount of symmetrical Dimethyl Arginine (SDMA) in biolo...
|
|
WO/2016/121862A1 |
This anti-inflammatory drug, which contains a G0/G1 switch 2 (G0S2) inhibitor as the active ingredient, is useful as a novel anti-inflammatory drug.
|
|
WO/2016/110822A1 |
The invention relates to a novel creatine derivative, the carboxylic biacyl creatine derivative of formula (I) and pharmaceutically acceptable salts thereof, methods of synthesis and the use thereof in the treatment of pathologies due to...
|
|
WO/2016/108045A2 |
The invention discloses compounds of the formula wherein A, B, X, Y and Z are defined. The compounds of the invention show activity against a range of bacteria, and are useful in the treatment or prophylaxis of a bacterial infection in a...
|
|
WO/2016/105449A1 |
This disclosure provides compounds and compositions for use as analgesics and for the treatment of one or more conditions selected from: pain; psychic pain; psychological pain; psychiatric pain; depression; allodynia; fibromyalgia; fibro...
|
|
WO/2016/105448A1 |
This disclosure provides compounds and compositions for use as analgesics and for the treatment of various conditions, such as pain, headaches, allodynia, and fibromyalgia. The disclosure also provides compounds that are ligands, and in ...
|
|
WO/2016/102323A1 |
The present invention relates to processes for increasing the stability of compositions comprising polyunsaturated omega-3 fatty acids against oxidation. The processes comprise the following steps: (i) providing a starting composition co...
|
|
WO/2016/102316A1 |
The present invention relates to processes for increasing the stability of compositions comprising polyunsaturated omega-6 fatty acids against oxidation. The processes comprise the following steps: (i) providing a starting composition co...
|
|
WO/2016/083471A1 |
The present patent application relates to new metal complexes having at least one N-aminoguanidinate ligand. The patent application further relates to the preparation of the new metal complexes and also to their use. The new metal comple...
|
|
WO/2016/070712A1 |
Disclosed are amino acid derivatives and applications thereof. The amino acid derivatives contain the oxalyl group, and thus can interfere with energy metabolism of cells and induce apoptosis. Therefore, the amino acid derivatives can be...
|
|
WO/2016/065322A1 |
The present disclosure provides purified forms of iobenguane and preparations of a precursor to iobenguane, such as a polymer, the polymer comprising a monomer of formula (I) or a pharmaceutically acceptable salt thereof, the preparation...
|
|
WO/2016/059507A1 |
The present invention provided an improved process for the preparation of Metformin compound of formula I or its pharmaceutically acceptable salts 5 thereof, by employing an alcoholic solvent throughout the process
|
|
WO/2016/055644A1 |
The present invention relates to linear guanidine derivatives, methods of preparation, uses and pharmaceutical compositions thereof. The compounds of Formulas 1 or 2 exhibit high antimicrobial activity against Gram positive and Gram nega...
|
|
WO/2016/015081A9 |
The invention relates to a method for producing polycondensation products of guanidine, aminoguanidine or diaminoguanidine G with one or more benzyl- or allyl-derivatives BA according to the following reaction scheme: wherein X represent...
|
|
WO/2016/033635A1 |
The invention provides compounds of Formula (I), and their use in methods for treating or preventing a protozoan infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in ...
|
|
WO/2016/029888A1 |
The present invention provides amphiphilic compounds with tetradecahydrophenanthrene skeleton and their enantiomers, exhibiting neuroprotective effects, their use as medicaments for treating neuropsychiatric disorders associated with an ...
|
|
WO/2016/028016A1 |
The present invention relates to a method for preparing D-arginine, and more specifically, to a method for preparing D-arginine by light-splitting DL-arginine by using D-3-Bromocamphor-10-sulfonic acid as a light-splitting agent.
|
|
WO/2016/025681A1 |
The disclosure provides compositions and methods for sensitizing primary HIV-1, including transmitted/founder viruses, to neutralization by monoclonal antibodies, e.g., those directed against CD4-induced (CD4i) epitopes and the V3 region...
|
|
WO/2016/001425A2 |
The invention relates to an electronic device comprising a compound having Formula (1): ABX (1), wherein A is a structural moiety that consists of at least two atoms and comprises a conjugated system of delocalized electrons, each B is i...
|
|
WO/2015/183794A1 |
Provided herein are complexes of metformin or metformin analogues and a TGR5 ligand that are useful in treating diseases including diabetes, cardiovascular disease, and cancer.
|
|
WO/2015/183545A1 |
The present disclosure relates to methods of using a compound to induce regeneration of hematopoietic stem cells or increase the recovery of red blood cells. In some aspects, the present methods can be used to with or in place of erythro...
|
|
WO/2015/168465A1 |
This invention relates to compounds that inhibit creatine transport and/or creatine kinase, pharmaceutical compositions including such compounds, and methods of utilizing such compounds and compositions for the treatment of cancer.
|
|
WO/2015/167243A1 |
The present invention relates to a novel compound capable of effectively preventing and treating immune diseases and a use thereof. The novel compound of the present invention has effects of inhibiting the production of inflammatory cyto...
|
|
WO/2015/158860A1 |
The invention relates to a composition comprising at least one polymer that contains silane groups and at least one catalyst of formula (I), said catalyst having specific amidine groups or guanidine groups. The composition is low in emis...
|
|
WO/2015/160220A1 |
The present invention relates to guanidine compounds for inhibiting mitochondrial oxidative phosphorylation (OXPHOS) and use thereof. More specifically, the present invention relates to a pharmaceutical composition for preventing or trea...
|
|
WO/2015/158862A1 |
The invention relates to a composition, comprising a) at least one silane-functional polymer; and b) at least one carbodimide and/or at least one guanidine, which is an adduct of the carbodiimide and an amino silane. The composition is i...
|
|
WO/2015/158863A1 |
The invention relates to a composition comprising at least one organic polymer that contains silane groups and at least one catalyst of formula (I). The composition is low in emissions and low-odour, has a good shelf-life, cures rapidly ...
|
|
WO/2015/146882A1 |
By adding carbobenzoxy chloride and a basic group in a water/organic solvent bilayer system to arginine or an arginine derivative (1) which are represented by belowmentioned formula (1), or a salt of said arginine derivative (1), the arg...
|
